Hong Kong Exchanges and Clearing Limited, the Stock Exchange of Hong Kong Limited, and Hong Kong Securities Clearing Company Limited disclaim all responsibility for the announcement by Sichuan Biokin Pharmaceutical Co., Ltd. (Stock Code: 2615). The securities have not been and will not be registered under the United States Securities Act of 1933 or the laws of any state in the United States, and no public offer of securities will be made in the United States.

According to the Company’s Prospectus dated November 7, 2025, the Global Offering was scheduled to begin on November 17, 2025. Due to prevailing market conditions, the Company, in consultation with the Overall Coordinators, has decided to postpone the Global Offering. Consequently, the International Underwriting Agreement will not be entered into, and the Hong Kong Underwriting Agreement will not become unconditional.

All application monies for the Hong Kong Public Offering (including relevant fees and levies) will be refunded in full without interest. Applicants using the White Form eIPO service should expect White Form e-Refund payment instructions or refund cheques to be dispatched on or before Monday, November 17, 2025. Applicants using the HKSCC EIPO channel should contact their brokers or custodians regarding refund arrangements. H Share certificates for the Offer Shares have not been issued and will not be delivered.

The postponement does not affect the Company’s current business. The Company is evaluating an updated timetable and expresses gratitude to prospective investors for their support and feedback during the offering process. This announcement is dated November 12, 2025.

As of the date of the announcement, the Board of Sichuan Biokin Pharmaceutical Co., Ltd. comprises executive directors Dr. Zhu Yi, Ms. Zhang Suya, Mr. Zhuo Shi, Dr. Zhu Hai, and Dr. Wan Weili; non-executive director Dr. David Guowei Wang; and independent non-executive directors Mr. Li Mingyuan, Dr. Xiao Geng, and Dr. Dai Zewei.